Compare NPCE & EU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPCE | EU |
|---|---|---|
| Founded | 1997 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Other Metals and Minerals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.3M | 353.5M |
| IPO Year | 2021 | 2011 |
| Metric | NPCE | EU |
|---|---|---|
| Price | $15.53 | $2.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $18.33 | $4.00 |
| AVG Volume (30 Days) | 165.9K | ★ 2.3M |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.03 | 11.76 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $99,986,000.00 | $43,155,000.00 |
| Revenue This Year | $0.90 | $212.11 |
| Revenue Next Year | $24.46 | $29.88 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.13 | N/A |
| 52 Week Low | $7.56 | $1.27 |
| 52 Week High | $18.97 | $4.19 |
| Indicator | NPCE | EU |
|---|---|---|
| Relative Strength Index (RSI) | 62.85 | 57.28 |
| Support Level | $15.25 | $2.06 |
| Resistance Level | $15.71 | $2.17 |
| Average True Range (ATR) | 0.67 | 0.13 |
| MACD | 0.22 | 0.06 |
| Stochastic Oscillator | 92.94 | 93.62 |
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties of uranium resource properties in the United States. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's Projects are South Texas Operations, Dewey-Burdock Project, Gas Hills Project, Crownpoint & Hosta Butte Project, PFN (Prompt Fission Neutron) Technology, and Other Assets.